1. INTRODUCTION:

The central nervous system (CNS) is the most multifaceted and extremely protected systems in the human body. A major component responsible for maintaining its integrity is the blood–brain barrier (BBB), a dynamic and extremely selective boundary that isolates circulating blood from the neural tissue. The BBB plays a vivacious part in safeguarding the brain by limiting the entry of possibly damaging substances, pathogens, and toxins, while at the same time regulating the transition of essential nutrients and signalling molecules. This protective function, however, creates a formidable challenge for the transport of therapeutic agents intended to treat neurological disorders^1,2.

Neurological and neurodegenerative remain among the leading causes of disability and mortality worldwide³. Despite the discovery of numerous potential therapeutic molecules, their clinical translation is often hindered by the restrictive nature of the BBB. It is projected that more than 98% of small-molecules and almost 100% of large-molecules fail to effectively cross the BBB in therapeutically relevant concentrations. As a result, the development of efficient and safe strategies to overcome this physiological barrier has become a central focus in the field of CNS drug delivery⁴.

Traditional approaches to bypass the BBB—such as direct intracerebral administration or transient osmotic disruption—are either invasive, associated with significant risks, or lack long-term applicability. Advances in nanotechnology, molecular biology, and biomedical engineering have paved the way for the design of innovative methods capable of enhancing drug permeability across the BBB. Among these, nanocarriers, receptor-mediated delivery systems, gene therapy vectors, and biologically inspired strategies such as exosomes and peptides have gained increasing attention with minimal systemic toxicity⁵.

In this review, a comprehensive overview of the structure and function of the BBB, the major challenges associated with CNS drug delivery, and the current as well as emerging strategies designed to overcome this barrier are discussed.

2. Structure and Function of the BBB

Fig. 1: The structure of BBB ²

BBB is an extremely specialized and active interface that controls the transport of molecules, ions, and cells between the circulating blood and CNS. It ensures the maintenance of brain homeostasis, which is essential for proper neuronal signaling and overall CNS function. The BBB is not a single physical structure, but rather a neurovascular unit (NVU) made up of endothelial cells, astrocytes, pericytes, basement membrane, and associated neurons as shown in figure 1. Each component contributes uniquely to the barrier’s selective permeability⁶.

2.1 Endothelial Cells and Tight Junctions:

The endothelial cells of the cerebral microvasculature form the primary anatomical basis of the BBB. Unlike peripheral endothelial cells, brain endothelial cells are characterized by the presence of tight junction (TJ) complexes formed by proteins such as claudins, occludin, and junctional adhesion molecules. These proteins create a high transendothelial electrical resistance (TEER), effectively minimizing paracellular diffusion of hydrophilic solutes⁷. This tight sealing prevents uncontrolled passage of drugs, ions, and pathogens into the brain parenchyma. Additionally, these endothelial cells are devoid of fenestrations and exhibit low rates of pinocytosis, further reinforcing the restrictive nature of the barrier.

2.2 Astrocytic End-Feet:

Astrocytes play a supportive but critical part in preserving the integrity of the BBB. Their perivascular end-feet envelop approximately 99% of the brain capillary surface, providing both physical support and paracrine signalling⁸. Astrocytes release growth factors and cytokines which regulate endothelial tight junction formation and permeability. They also contribute to the regulation of water and ion homeostasis via channels like aquaporin-4 (AQP4), influencing the transport of solutes across the BBB.

2.3 Pericytes and Basement Membrane:

Embedded within the basement membrane, pericytes are contractile cells that wrap around brain capillaries. They are essential for angiogenesis, endothelial cell stability, and regulation of BBB permeability. Pericytes communicate directly with endothelial cells through gap junctions and signaling pathways, modulating vascular tone, clearance of toxic metabolites, and immune cell infiltration. The basement membrane, composed of extracellular matrix proteins such as laminin, collagen, and fibronectin, provides mechanical stability to the BBB and acts as a barrier to cell migration⁹.

2.4 Transport Mechanisms Across the BBB:

Despite its restrictive nature, the BBB permits selective transport of nutrients, ions, and signaling molecules required for CNS function. The main transport pathways include:

· Passive Diffusion: Small, lipophilic, and uncharged molecules (e.g., oxygen, carbon dioxide, ethanol, nicotine) can diffuse across the endothelial lipid bilayer without requiring carriers. However, only drugs with molecular weights below ~400–500 Da and high lipophilicity typically utilize this route.

· Carrier-Mediated Transport (CMT): Essential nutrients such as glucose, amino acids, and nucleosides cross the BBB via specific solute carriers (e.g., GLUT1 for glucose, LAT1 for large neutral amino acids). This pathway is highly selective and saturable.

· Receptor-Mediated Transport (RMT): Larger biomolecules such as transferrin, insulin, and leptin gain access through binding to endothelial receptors followed by endocytosis and transcytosis. This mechanism has been widely explored for drug delivery using ligand-modified nanocarriers.

· Adsorptive-Mediated Transcytosis (AMT): Cationic proteins and peptides interact with the negatively charged endothelial surface, facilitating vesicular uptake and transport across the BBB.

· Efflux Pumps: These efflux pumps actively expel xenobiotics and drugs back into the bloodstream, thereby reducing CNS drug accumulation and contributing to multidrug resistance in brain tumors and epilepsy^10,11,12.

3. Challenges in Drug Delivery across The BBB:

While BBB is essential for maintaining neural homeostasis, it poses formidable challenges to therapeutic drug delivery. Several interrelated factors contribute to the difficulty of achieving effective concentrations of drugs within the brain.

3.1 Molecular Weight Restrictions:

The BBB is formed by tightly joined endothelial cells, which restrict the paracellular movement of solutes. As a result, only molecules of small size, typically less than 400–500 Da, are able to cross the BBB by passive diffusion¹³. Larger therapeutic entities—including peptides, proteins, nucleic acids, antibodies, and many novel biologics—are generally excluded¹⁴. This limitation significantly hampers the application of advanced therapeutic modalities for neurological disorders. Consequently, most conventional small molecules that act in the CNS have been specifically optimized to meet these stringent size constraints.

3.2 Lipophilicity and Polarity Issues:

The physicochemical properties of drugs strongly influence their capability to cross the BBB. Lipophilicity plays a crucial role because the endothelial membranes are lipid-rich; moderately lipophilic molecules are more likely to diffuse across. However, the relationship is not straightforward.

· Excessively hydrophilic or polar molecules fail to diffuse, as they are repelled by the lipid bilayer and remain trapped in systemic circulation.

· Overly lipophilic drugs, on the other hand, may partition into the endothelial membrane, where they become sequestered or bind extensively to plasma proteins, reducing free drug availability. Thus, achieving an optimal balance between lipophilicity and hydrophilicity is critical. This requirement imposes limitations on chemical diversity during CNS drug discovery, often forcing medicinal chemists to compromise on potency, solubility, or stability to achieve BBB permeability¹⁵.

3.3 Efflux Transporter Activity:

One of the most significant biological barriers to CNS drug delivery is the presence of efflux transporters. The luminal surface of BBB endothelial cells is enriched with ATP-binding cassette (ABC) transporters, such as:

· P-glycoprotein (P-gp/ABCB1)

· Breast cancer resistance protein (BCRP/ABCG2)

· Multidrug resistance-associated proteins (MRPs)

These proteins actively pump a wide spectrum of structurally diverse compounds—including many therapeutic drugs—back into the bloodstream, even after they have diffused into the endothelial cells. This protective mechanism, while crucial for preventing CNS toxicity from xenobiotics, drastically lowers the effective brain concentration of drugs such as anticancer agents, antivirals, and antidepressants. In many cases, clinical trial failures of promising CNS drugs have been attributed to efflux transporter activity rather than lack of intrinsic pharmacological activity¹⁶.

3.4 Enzymatic Degradation:

In addition to physical and transporter-mediated barriers, the BBB also exerts a metabolic barrier through its enzymatic machinery¹⁷. Endothelial cells of the BBB express a variety of drug-metabolizing enzymes, including Phase I enzymes (cytochrome P450 isoforms, monoamine oxidases), Phase II enzymes (glucuronyltransferases, sulfotransferases), Hydrolases and peptidases. These enzymes degrade or chemically modify many therapeutic molecules before they can enter the CNS. Peptide- and protein-based therapeutics are particularly vulnerable, as they are rapidly cleaved into inactive fragments. This metabolic activity further reduces effective brain penetration, even for drugs with otherwise favorable physicochemical properties. Moreover, enzymatic degradation often produces metabolites with altered pharmacological or toxicological profiles, complicating drug design and safety evaluation¹⁸.

4. Conventional Approaches to Cross The BBB:

Over the years, several conventional strategies have been developed to improve the delivery of therapeutic molecules into the brain. Although many of these methods have shown promise in preclinical and clinical studies, they often come with significant limitations such as invasiveness, toxicity, or lack of specificity. The major approaches include chemical modifications of drugs, temporary disruption of the BBB, and direct invasive delivery techniques.

4.1 Chemical Modification of Drugs:

One of the earliest strategies to enhance BBB permeability involves modifying the physicochemical properties of drugs to promote passive diffusion across the barrier. A common approach is the use of prodrugs, wherein an inactive or less active derivative of the parent drug is chemically modified (e.g., through esterification or amidation) to increase lipophilicity or reduce polarity. These modifications allow the prodrug to cross the BBB more efficiently, after which enzymatic or chemical processes within the CNS convert it into the active form. Classic examples include L-DOPA, which traverses the BBB and is subsequently decarboxylated into dopamine, as well as ester-based prodrugs of antiviral agents. Another strategy is lipophilization, where hydrophobic functional groups are introduced to small molecules to enhance their ability to partition into the lipid bilayer of endothelial cells. However, excessive lipophilicity can lead to drug sequestration within membranes or rapid systemic clearance, underscoring the importance of achieving an optimal balance in drug design. Despite being relatively straightforward, these methods are limited by the restricted chemical flexibility of certain drug classes and the unpredictability of prodrug activation^19,20.

4.2 Disruption of the BBB:

Another conventional strategy to enhance drug delivery to the brain is the temporary and localized disruption of the BBB, which facilitates the entry of therapeutic agents. One approach is osmotic disruption, where administration of hyperosmotic agents such as mannitol induces endothelial cell shrinkage, resulting in the transient opening of tight junctions and increased paracellular permeability. This technique has been applied clinically for the delivery of chemotherapeutic agents in brain tumors. A more recent advancement is focused ultrasound (FUS), which, when combined with intravenously administered microbubbles, employs low-frequency ultrasound waves to selectively and transiently disrupt the BBB in specific regions. This non-invasive method enhances localized drug permeability while minimizing systemic exposure. Despite their effectiveness, such BBB-disruption strategies raise significant safety concerns, as they may permit the nonspecific entry of toxins, pathogens, or plasma proteins into the central nervous system, potentially causing neurotoxicity or inflammation²¹.

4.3 Invasive Techniques:

Direct administration of drugs into the cerebrospinal fluid (CSF) offers a way to completely bypass the BBB ²². Intracerebroventricular (ICV) injection delivers drugs directly into the cerebral ventricles, enabling wide CSF distribution and has been applied for protein therapeutics and gene therapies. Similarly, intrathecal administration introduces drugs into the spinal canal, ensuring CSF availability and subsequent distribution to both the brain and spinal cord. Although these approaches achieve high local drug concentrations, they are invasive, associated with risks such as infection and tissue damage, and often necessitate repeated dosing or implanted catheters, which reduce patient compliance and limit clinical practicality.

5. Nanotechnology-Based Strategies to Cross The BBB

Fig. 2: Nanotechnology-based approaches to cross BBB.

Nanotechnology has emerged as a revolutionary approach for overcoming the challenges of drug delivery to the CNS. Nanocarriers, with their tunable physicochemical properties, can be engineered to protect therapeutic agents, enhance permeability across the BBB, and provide controlled or targeted release. Their small size (typically 10–200nm), surface modifiability, and versatility make them ideal candidates for CNS drug delivery. Several classes of nanocarriers are being actively investigated and are shown in Figure 2.

5.1 Lipid-Based Nanocarriers:

Lipid-based nanocarriers, which closely mimic biological membranes, exhibit excellent biocompatibility and facilitate interactions with BBB endothelial cells. Among these, liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic drugs in their aqueous core and lipophilic drugs within the lipid bilayer. Surface PEGylation extends their circulation time, while ligand conjugation (e.g., transferrin, lactoferrin) enables receptor-mediated BBB transport. Solid lipid nanoparticles (SLNs), formed from solid lipid matrices, provide stability, controlled release, and low toxicity, making them particularly suitable for lipophilic drugs. Nanostructured lipid carriers (NLCs), a more advanced version of SLNs, incorporate both solid and liquid lipids, introducing structural imperfections that enhance drug loading capacity and minimize drug expulsion during storage. Collectively, lipid-based nanocarriers hold strong potential for CNS delivery due to their high biocompatibility, but limitations such as rapid clearance by the reticuloendothelial system (RES) and difficulties in large-scale production remain significant challenges ^23,24.

5.2 Polymeric Nanoparticles:

Polymeric nanoparticles are solid colloidal carriers fabricated from biodegradable and biocompatible polymers, offering sustained drug release and versatile surface functionalization for targeted CNS delivery. Among these, poly (lactic-co-glycolic acid) (PLGA) is the most extensively used FDA-approved polymer, as it degrades into lactic and glycolic acid—both naturally metabolized by the body. PLGA nanoparticles enable controlled release of drugs, accommodate both hydrophilic and hydrophobic molecules, and can be surface-functionalized with targeting ligands to enhance BBB penetration. Another notable system is chitosan-based nanoparticles, derived from the natural polymer chitin. Chitosan is biocompatible, mucoadhesive, and capable of transiently opening tight junctions, thereby enhancing paracellular transport across the BBB. These nanoparticles are particularly advantageous for intranasal delivery, offering a non-invasive route to the CNS. Despite their promise, polymeric nanoparticles face challenges related to polymer degradation by-products, potential toxicity, and difficulties in achieving reproducibility during large-scale manufacturing^25,26.

5.3 Dendrimers and Micelles:

Dendrimers are highly branched, nanosized synthetic polymers with a tree-like architecture that provides numerous terminal functional groups for drug loading, surface conjugation with targeting ligands, or incorporation of imaging agents. Poly(amidoamine) (PAMAM) dendrimers, in particular, have demonstrated potential in delivering anticancer and anti-inflammatory drugs across the BBB. Another versatile system is polymeric micelles, which are self-assembled nanosized carriers formed by amphiphilic block copolymers. Their hydrophobic core enables solubilization of poorly water-soluble drugs, while the hydrophilic shell prolongs circulation time and enhances systemic stability. Furthermore, surface functionalization with BBB-specific ligands can significantly improve brain uptake. Although both dendrimers and polymeric micelles offer promising flexibility and functionality, their clinical translation requires careful toxicity evaluation, as they may accumulate in tissues and raise long-term safety concerns^27,28.

5.4 Nanosponges and Exosomes:

Nanosponges are porous, sponge-like nanocarriers, often composed of cyclodextrin-based polymers, capable of entrapping both hydrophilic and lipophilic drugs. They provide controlled release, can be surface-modified for active targeting, and demonstrate strong potential for crossing biological barriers, making them attractive candidates for CNS applications. In parallel, exosomes—naturally secreted extracellular vesicles—have emerged as highly promising delivery systems due to their intrinsic biocompatibility, stability in circulation, and innate ability to cross the BBB. Exosomes can transport diverse therapeutic cargos, including proteins, nucleic acids, and small molecules, and their membrane composition can be engineered to enhance targeting efficiency. Despite this promise, large-scale production, isolation, and purification of exosomes remain critical challenges. Overall, nanotechnology-based approaches—including nanosponges, exosomes, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, dendrimers, and micelles—offer unique advantages such as protection of drugs from enzymatic degradation, enhanced permeability and retention, controlled release, and opportunities for active targeting. However, barriers to clinical translation remain, particularly those related to large-scale manufacturing, regulatory approval, immune recognition, and the potential for long-term toxicity. Addressing these limitations will be essential for realizing the full potential of nanocarrier-based strategies in CNS drug delivery^29,30.

6. Biological and Receptor-Mediated Approaches to Cross The BBB:

Unlike conventional or nanotechnology-based approaches that often rely on passive transport or physical disruption, biological and receptor-mediated strategies exploit the endogenous transport mechanisms of the BBB. By mimicking or hijacking these natural pathways, therapeutic molecules—including peptides, proteins, nucleic acids, and small-molecule drugs—can be selectively transported into the brain with higher efficiency and specificity.

6.1 Receptor-Mediated Transport (RMT):

RMT is a highly specific strategy that leverages endocytosis and transcytosis mechanisms, wherein ligands bind to receptors on the luminal surface of BBB endothelial cells and are subsequently shuttled into the CNS. Among the most extensively studied systems are transferrin receptors (TfR), which allow therapeutic agents or nanocarriers conjugated with transferrin or anti-TfR antibodies to exploit iron transport pathways for BBB penetration³¹. Insulin receptors have also been targeted, primarily for the delivery of peptides and proteins through conjugation with insulin or insulin-like molecules. In addition, low-density lipoprotein (LDL) receptors and related scavenger receptors serve as entry points for lipoprotein-mimicking nanoparticles or apolipoprotein-modified carriers. RMT demonstrates strong potential for the delivery of chemotherapeutics, enzymes for lysosomal storage disorders, and neurotrophic factors. However, challenges such as competition with endogenous ligands, potential receptor saturation, and variability in receptor expression across patient populations limit its universal applicability.

6.2 Carrier-Mediated Transport (CMT):

CMT takes advantage of endogenous nutrient transporters at the BBB that support neuronal metabolism by shuttling essential small molecules into the CNS. Glucose transporters (GLUT1) have been widely exploited for the delivery of glucose-conjugated drugs or nanoparticles. Similarly, amino acid transporters such as LAT1 and CAT1 facilitate the entry of amino acid–mimicking drugs, with L-DOPA serving as the classic example in Parkinson’s disease therapy³². Nucleoside and monocarboxylate transporters have also been targeted for the delivery of nucleoside analogs and lactate/pyruvate-conjugated therapeutics. While the CMT approach is highly efficient for small-molecule drugs, its application to macromolecules remains limited. Furthermore, competition with endogenous substrates can significantly reduce drug transport efficiency, posing a major hurdle for translation.

6.3 Cell-Penetrating Peptides (CPPs):

CPPs are short, typically cationic or amphipathic sequences—such as the HIV-derived TAT peptide, penetratin, and polyarginine—that facilitate non-receptor-mediated uptake across cellular membranes, including the endothelial cells of the BBB. They promote drug penetration through mechanisms like endocytosis or direct translocation and can be conjugated to diverse cargos, including proteins, nucleic acids, nanoparticles, and imaging agents, to enhance brain uptake³³. CPP-based delivery systems are versatile and relatively straightforward to design; however, their clinical utility is limited by poor tissue selectivity, rapid systemic clearance, and the risk of off-target toxicity due to indiscriminate penetration into non-CNS tissues.

6.4 Monoclonal Antibodies (Trojan Horse Strategy):

The Trojan horse approach employs engineered monoclonal antibodies (mAbs) or antibody fragments that selectively bind to BBB receptors such as transferrin or insulin receptors. These antibody–drug conjugates or antibody-functionalized nanocarriers are recognized as natural ligands, internalized through receptor-mediated endocytosis, and subsequently transcytosed into the brain³⁴. This strategy has been successfully investigated for the delivery of therapeutic enzymes in lysosomal storage disorders, neurotrophic factors in neurodegenerative conditions, and even gene therapy vectors. Its key advantage lies in the high selectivity and efficiency of receptor targeting, which allows macromolecules to cross the BBB with precision. However, limitations such as high production costs, the risk of immune responses, and competition with endogenous ligands restrict its broad clinical application. Overall, biological and receptor-mediated strategies—including RMT, CMT, CPPs, and the Trojan horse approach—are among the most clinically relevant methods for BBB drug delivery, as they exploit inherent physiological processes. These approaches provide target specificity, enable the delivery of large biomolecules, and reduce systemic side effects. Yet, challenges such as receptor saturation, limited transport capacity, immune reactivity, and patient-to-patient variability remain critical barriers to widespread translation into routine clinical practice.

7. Advanced and Emerging Techniques to Cross The BBB:

While conventional and nanotechnology-based methods have laid the foundation for CNS drug delivery, recent advances in biotechnology, genetic engineering, and bio-inspired systems have introduced next-generation strategies. These approaches aim to overcome the intrinsic limitations of earlier methods by offering greater precision, efficiency, and potential for personalization in treating neurological disorders.

7.1 Exosome-Mediated Delivery:

Exosomes are nanosized extracellular vesicles (30–150 nm) secreted by most cell types, naturally functioning in intercellular communication through the transfer of proteins, lipids, and nucleic acids. Their inherent ability to cross the BBB makes them highly attractive as biocompatible drug delivery carriers. Exosomes can be engineered for therapeutic applications by loading them with small molecules, proteins, or nucleic acids such as siRNA and miRNA³⁵. Furthermore, surface modification with ligands or antibodies enables precise targeting to specific brain cells, including neurons, astrocytes, and microglia. Key advantages of exosome-based delivery include excellent biocompatibility, immune tolerance, and stability in circulation. However, major challenges—particularly large-scale isolation, purification, and standardization—must be addressed before exosomes can be translated into widespread clinical use.

7. 2. Gene Therapy Vectors:

Viral vectors represent a powerful approach for direct gene delivery across the BBB, enabling correction of genetic defects or modulation of disease pathways. Adeno-associated viruses (AAVs) are the most extensively studied, with certain serotypes such as AAV9 and AAV-PHP.B exhibiting natural tropism for CNS tissues. Their clinical relevance is highlighted by FDA-approved therapies like onasemnogene abeparvovec, used in the treatment of spinal muscular atrophy³⁶. Lentiviruses, in contrast, are integrating vectors that allow long-term expression of therapeutic genes and are frequently employed in ex vivo strategies, where patient-derived cells are genetically modified before transplantation³⁷. Despite their high efficiency and durability, viral vector–based delivery is constrained by significant safety and regulatory challenges, including immunogenicity, off-target effects, and the risk of insertional mutagenesis.

7.3 CRISPR/Cas Systems for Neurological Disorders:

Genome-editing technologies, particularly CRISPR/Cas9, are emerging as transformative tools for treating neurological disorders by directly correcting mutations implicated in conditions such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy³⁸. Effective delivery across the BBB is generally achieved using adeno-associated virus (AAV) vectors, lipid nanoparticles, or engineered exosomes as carriers. Unlike conventional therapies that provide only symptomatic relief, CRISPR-based approaches offer the possibility of permanent gene correction, representing a potential cure for otherwise intractable CNS diseases. Despite this promise, critical challenges remain, including the need for precise and efficient delivery, assurance of long-term safety, and minimization of off-target genome edits, all of which must be addressed before clinical translation becomes feasible.

7.4 Nanobody-Based Targeting:

Nanobodies, also known as single-domain antibody fragments, are derived from camelid heavy-chain antibodies and possess distinctive advantages for BBB-targeted applications. With their small size (~15 kDa), high stability, and strong binding affinity, nanobodies can be engineered to interact with BBB receptors such as transferrin and insulin receptors, enabling receptor-mediated transcytosis into the CNS. In addition to acting as carriers for therapeutic molecules, nanobodies hold promise as imaging agents due to their superior tissue penetration compared with conventional monoclonal antibodies. Although their clinical potential is substantial, challenges related to large-scale production, immunogenicity, and regulatory validation must be addressed to advance their translation into routine practice.

8. Future Perspectives in Bbb Drug Delivery:

The development of effective strategies to traverse the BBB remains central to advancing therapies for neurological disorders. Although significant progress has been achieved through nanotechnology, biological targeting, and emerging gene-editing systems, several challenges continue to impede clinical translation. Looking ahead, future research is expected to focus on personalized approaches, innovative in vitro models, and careful evaluation of ethical and translational hurdles.

8.1 Personalized Medicine Approaches:

The heterogeneity of neurological diseases and the variability of BBB characteristics among individuals underscore the importance of patient-specific therapeutic strategies. Genetic and epigenetic factors can significantly influence transporter expression, receptor density, and BBB integrity, suggesting that personalized molecular profiling may guide the optimal selection of drugs and design of delivery systems. Biomarker-driven targeting further enables the identification of patient subgroups most likely to respond to BBB-penetrating therapies. Precision nanomedicine—where nanocarriers are functionalized with patient-specific ligands, antibodies, or targeting moieties—holds particular promise for individualized CNS treatment. Ultimately, integrating pharmacogenomics with tailored drug-delivery platforms could improve therapeutic efficacy, reduce adverse effects, and move the field closer to truly personalized CNS therapy.

8.2 Artificial BBB Models and Organ-on-Chip Systems:

Conventional preclinical models, particularly animal studies, often fail to accurately predict human BBB permeability due to species-specific differences, which significantly contribute to the high attrition rate of CNS drug candidates during clinical development. To overcome these limitations, advanced in vitro platforms have been developed. Artificial BBB models derived from human cell cultures provide rapid and reproducible systems for assessing drug permeability and transporter interactions. More sophisticated approaches include microfluidic organ-on-chip systems that replicate the dynamic BBB microenvironment, incorporating factors such as shear stress, multicellular interactions, and real-time monitoring of molecular transport, thereby enhancing physiological relevance⁴¹. Additionally, integration of 3D bioprinting technologies and stem cell-derived endothelial cells has further improved model fidelity, narrowing the translational gap between laboratory findings and clinical outcomes. Collectively, these advanced systems are expected to accelerate CNS drug discovery, reduce reliance on animal testing, and improve the predictive accuracy of BBB penetration in humans.

9. CONCLUSION:

Over the past decades, significant progress has been made in developing strategies to overcome the formidable challenge of the BBB. Conventional approaches such as chemical modification of drugs, osmotic disruption, and invasive delivery techniques laid the early foundation but were limited by invasiveness, non-specificity, and safety concerns. Nanotechnology-based carriers, including liposomes, polymeric nanoparticles, dendrimers, and exosomes, have since provided more refined solutions, enabling controlled release, enhanced permeability, and active targeting. In parallel, biological and receptor-mediated approaches—such as receptor-mediated transport, carrier-mediated systems, and monoclonal antibody “Trojan horse” strategies—have leveraged endogenous pathways to achieve more selective and physiologically compatible delivery. More recently, advanced and emerging platforms such as exosome engineering, gene therapy vectors, CRISPR/Cas systems, nanobody-based targeting, and hybrid nanoparticles represent the cutting edge of translational innovation.

Despite these advances, major challenges remain. Transport efficiency across the BBB is still limited, and many strategies face hurdles related to immune recognition, receptor competition, and potential off-target effects. Issues of scalability, reproducibility, regulatory approval, and long-term safety continue to delay clinical translation. Furthermore, inter-patient variability in BBB physiology complicates the design of universal delivery systems, underscoring the need for personalized medicine approaches.

Looking ahead, the translational potential for treating CNS diseases is immense. With the integration of nanotechnology, molecular biology, and bioengineering, alongside artificial BBB models and organ-on-chip platforms, more predictive preclinical testing is now possible. These innovations, combined with personalized profiling and ethical oversight, pave the way for tailored and effective therapies. Ultimately, the convergence of these multidisciplinary strategies offers hope that the long-standing barrier of the BBB will be transformed into a gateway for delivering life-changing treatments for neurodegenerative disorders, brain tumors, and other CNS pathologies.

10. ACKNOWLEDGEMENT:

The authors are thankful to Divine College of Pharmacy, Satana for providing the necessary support for writing this review.

11. CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

12. REFERENCES:

1. Daneman R, Prat A. The Blood–Brain Barrier. Cold Spring Harb Perspect Biol. 2015 Jan;7(1): a020412. doi:10.1101/cshperspect. a020412.

2. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: Structure, regulation and drug delivery. Sig Transduct Target Ther. 2023 May;8(1):217. doi:10.1038/s41392-023-01481-w.

3. Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020 Mar;19(3):255–65. doi:10.1016/S1474-4422(19)30411-9.

4. Pardridge WM. The blood–brain barrier: Bottleneck in brain drug development. Neurotherapeutics. 2005 Jan; 2(1): 3–14. doi:10.1602/neurorx.2.1.3.

5. Sharma A, Dhiman K, Sharma A, Goyal K, Pandit V, Ashawat MS, Jindal S. Application of nanocarrier in drug development with special emphasis on liposomes: a review. Asian J Pharm Technol. 2022; 12(4): 320–8.

6. McConnell HL, Mishra A. Cells of the Blood–Brain Barrier: An Overview of the Neurovascular Unit in Health and Disease. In: Stone N, editor. The Blood–Brain Barrier. New York (NY): Springer US; 2022;3–24. (Methods in Molecular Biology; vol. 2492). doi:10.1007/978-1-0716-2289-61

7. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012 Dec;9(1):23. doi:10.1186/2045-8118-9-23.

8. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells. Nat Commun. 2014 Jun;5(1):4196. doi:10.1038/ncomms5196.

9. Stratman AN, Davis GE. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal. 2012 Feb; 18(1): 68–80. doi:10.1017/S1431927611012402.

10. Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood–brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016 Dec; 6(4): 225–48. doi:10.15171/bi.2016.30.

11. Ronaldson PT, Davis TP. Transport mechanisms at the blood–brain barrier and in cellular compartments of the neurovascular unit: focus on CNS delivery of small molecule drugs. Pharmaceutics. 2022 Jul; 14(7): 1501. doi:10.3390/pharmaceutics14071501.

12. Alajangi HK, Kaur M, Sharma A, Rana S, Thakur S, Chatterjee M, et al. Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Mol Brain. 2022 Dec; 15(1): 49. doi:10.1186/s13041-022-00937-4.

13. Hajal C, Campisi M, Mattu C, Chiono V, Kamm RD. In vitro models of molecular and nano-particle transport across the blood–brain barrier. Biomicrofluidics. 2018 Jul; 12(4): 042213. doi:10.1063/1.5027118.

14. Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood–brain barrier. Perspect Medicin Chem. 2014 Jan; 6: PMC.S13384. doi:10.4137/PMC.S13384.

15. Sirisha S, Praveena R. A complete review – nanoparticles targeting to brain. Asian J Res Pharm Sci. 2020; 10(3): 199. doi:10.5958/2231-5659.2020.00038.7.

16. Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood–brain barrier for brain cancer therapy. Theranostics. 2022; 12(10): 4734–52. doi:10.7150/thno.69682.

17. Sirisha S. A review on delivery of anti-cancer drugs by smart nanocarriers: data obtained from past one decade. Res J Pharm Dosage Forms Technol. 2020; 12(3): 185–90.

18. Leclerc M, Dudonné S, Calon F. Can natural products exert neuroprotection without crossing the blood–brain barrier? Int J Mol Sci. 2021 Mar; 22(7): 3356. doi:10.3390/ijms22073356.

19. Hersh DS, Wadajkar AS, Roberts NB, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood–brain barrier. Curr Pharm Des. 2016 Mar; 22(9): 1177–93. doi:10.2174/1381612822666151221150733.

20. Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014 May; 2241. doi:10.2147/IJN.S61288.

21. McLoughlin CD, Nevins S, Stein JB, Khakbiz M, Lee K. Overcoming the blood–brain barrier: multifunctional nanomaterial-based strategies for targeted drug delivery in neurological disorders. Small Sci. 2024 Dec; 4(12): 2400232. doi:10.1002/smsc.202400232.

22. Gernert M, Feja M. Bypassing the blood–brain barrier: direct intracranial drug delivery in epilepsies. Pharmaceutics. 2020 Nov; 12(12): 1134. doi:10.3390/pharmaceutics12121134.

23. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood–brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces. 2023 Jan; 221: 112999. doi: 10.1016/j.colsurfb.2022.112999.

24. Satapathy T, Panda PK. Solid lipid nanoparticles: a novel carrier in drug delivery system. Res J Pharm Dosage Forms Technol. 2013;5(2):56–61.

25. Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges. Adv Sci. 2021 May; 8(10): 2003937. doi:10.1002/advs.202003937.

26. Wu Y, Moonshi SS, Ta HT. Advancements in using polymeric nanoparticles for blood–brain barrier penetration in neurological disorders. ACS Appl Bio Mater. 2025 Jun; 8(6): 4416–31. doi:10.1021/acsabm.4c01956.

27. Ravind M, Kumar PS, Begum SKA. An overview of dendrimers as novel carriers in drug delivery. Res J Pharm Technol. 2023; 16(4): 2051–6.

28. Wang J, Wang Z, Zhang G, Rodrigues J, Tomás H, Shi X, et al. Blood–brain barrier-crossing dendrimers for glioma theranostics. Biomater Sci. 2024;12(6):1346–56. doi:10.1039/D4BM00043A.

29. Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into exosome transport through the blood–brain barrier and the potential therapeutical applications in brain diseases. Pharmaceuticals. 2023 Apr; 16(4): 571. doi:10.3390/ph16040571.

30. Alrubaye YSJ, Mohammed MB, Abdulamir HA. Exosome and breast cancer. Res J Pharm Technol. 2022; 15(3): 1393–7.

31. Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007 Aug;24(9):1759–71. doi:10.1007/s11095-007-9379-0.

32. Ding L, Kshirsagar P, Agrawal P, Murry DJ. Crossing the blood–brain barrier: innovations in receptor- and transporter-mediated transcytosis strategies. Pharmaceutics. 2025 May; 17(6): 706. doi:10.3390/pharmaceutics17060706.

33. Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020 May; 11:697. doi:10.3389/fphar.2020.00697.

34. Pardridge WM. Molecular Trojan horses for blood–brain barrier drug delivery. Curr Opin Pharmacol. 2006 Oct; 6(5): 494–500. doi: 10.1016/j.coph.2006.06.001.

35. Patel KK, Patel BS, Prajapati A, Narkhede SB, Luhar S. The exosome revolution: bridging early detection and personalized treatment. Res J Pharm Dosage Forms Technol. 2025; 17(1): 26–30.

36. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019 May; 18(5): 358–78. doi:10.1038/s41573-019-0012-9.

37. PM. Patil, PD Chaudhari, Megha Sahu, NJ Duragkar. Review Article on Gene Therapy. Research J. Pharmacology and Pharmacodynamics. 2012; 4(2): 77-83.

38. Nouri Nojadeh J, Bildiren Eryılmaz NS, Ergüder Bİ. CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI J. 2023; 22: Doc567. doi:10.17179/EXCLI2023-6155

39. Swapnaa B, Santhosh Kumar V. Personalized Medicine - A Novel approach in Cancer Therapy. Research J. Pharm. and Tech. 2017; 10(1): 341-345.\

40. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research J. Pharm. and Tech 2019; 12(8):3989-3992.

41. Chaulagain B, Gothwal A, Lamptey RNL, Trivedi R, Mahanta AK, Layek B, et al. Experimental models of in vitro blood–brain barrier for CNS drug delivery: an evolutionary perspective. Int J Mol Sci. 2023 Jan; 24(3): 2710. doi:10.3390/ijms24032710.

Received on 06.09.2025 Revised on 24.11.2025

Accepted on 29.01.2026 Published on 02.07.2026

Available online from July 15, 2026

Asian J. Res. Pharm. Sci. 2026; 16(3):234-242.

DOI: 10.52711/2231-5659.2026.00035

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.